| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Analgesics, Opioid | 41 | 2023 | 1371 | 6.340 |
Why?
|
| Pain, Postoperative | 26 | 2024 | 610 | 5.040 |
Why?
|
| Analgesia, Epidural | 12 | 2022 | 102 | 3.950 |
Why?
|
| Anesthesia | 10 | 2021 | 296 | 3.910 |
Why?
|
| Perioperative Care | 15 | 2023 | 451 | 3.540 |
Why?
|
| Analgesia | 7 | 2024 | 94 | 3.490 |
Why?
|
| Anesthesia, Conduction | 7 | 2024 | 42 | 3.490 |
Why?
|
| Hyperthermia, Induced | 11 | 2021 | 510 | 3.080 |
Why?
|
| Nerve Block | 7 | 2021 | 176 | 3.020 |
Why?
|
| Cytoreduction Surgical Procedures | 10 | 2021 | 475 | 2.700 |
Why?
|
| Neoplasms | 29 | 2023 | 15193 | 2.520 |
Why?
|
| Propofol | 4 | 2023 | 80 | 2.430 |
Why?
|
| Anesthetics | 4 | 2023 | 115 | 2.310 |
Why?
|
| Craniotomy | 6 | 2018 | 304 | 2.300 |
Why?
|
| Pain Management | 15 | 2024 | 668 | 2.210 |
Why?
|
| Analgesics | 10 | 2023 | 390 | 2.070 |
Why?
|
| Intraoperative Care | 9 | 2020 | 259 | 1.780 |
Why?
|
| Anesthesiology | 3 | 2021 | 138 | 1.700 |
Why?
|
| Dexmedetomidine | 6 | 2023 | 85 | 1.670 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 5 | 2020 | 521 | 1.600 |
Why?
|
| Anesthesia, General | 11 | 2023 | 239 | 1.560 |
Why?
|
| Receptors, Opioid, mu | 5 | 2021 | 86 | 1.480 |
Why?
|
| Acute Kidney Injury | 8 | 2021 | 739 | 1.450 |
Why?
|
| Intubation, Intratracheal | 7 | 2023 | 445 | 1.420 |
Why?
|
| Postoperative Complications | 23 | 2023 | 5542 | 1.410 |
Why?
|
| Neurosurgical Procedures | 5 | 2018 | 609 | 1.380 |
Why?
|
| Anesthesia, Epidural | 2 | 2021 | 31 | 1.330 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 11 | 2022 | 5319 | 1.330 |
Why?
|
| Lung Neoplasms | 15 | 2022 | 11538 | 1.290 |
Why?
|
| Humans | 156 | 2024 | 261506 | 1.270 |
Why?
|
| Cancer Pain | 4 | 2021 | 312 | 1.250 |
Why?
|
| Ketamine | 3 | 2022 | 234 | 1.210 |
Why?
|
| Anesthetics, Local | 9 | 2022 | 163 | 1.180 |
Why?
|
| Pain | 14 | 2023 | 1658 | 1.180 |
Why?
|
| Anesthesia, Spinal | 2 | 2017 | 18 | 1.130 |
Why?
|
| Lidocaine | 4 | 2022 | 76 | 1.120 |
Why?
|
| Erythrocyte Transfusion | 2 | 2021 | 212 | 1.120 |
Why?
|
| Retrospective Studies | 58 | 2023 | 37905 | 1.110 |
Why?
|
| Receptors, Opioid | 2 | 2023 | 35 | 1.080 |
Why?
|
| Neoplasm Recurrence, Local | 18 | 2024 | 10035 | 1.060 |
Why?
|
| Acute Pain | 3 | 2021 | 42 | 1.050 |
Why?
|
| Analgesia, Patient-Controlled | 6 | 2023 | 59 | 0.980 |
Why?
|
| Persons With Hearing Impairments | 1 | 2023 | 6 | 0.920 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2017 | 461 | 0.900 |
Why?
|
| Glioblastoma | 4 | 2017 | 1797 | 0.890 |
Why?
|
| Peripheral Nervous System Diseases | 7 | 2022 | 393 | 0.890 |
Why?
|
| Opioid-Related Disorders | 4 | 2022 | 394 | 0.880 |
Why?
|
| Peritoneal Neoplasms | 2 | 2021 | 821 | 0.870 |
Why?
|
| Esophagectomy | 2 | 2018 | 911 | 0.860 |
Why?
|
| Monitoring, Intraoperative | 4 | 2019 | 264 | 0.850 |
Why?
|
| Pain Measurement | 16 | 2023 | 953 | 0.850 |
Why?
|
| Perioperative Period | 6 | 2020 | 155 | 0.830 |
Why?
|
| Cigarette Smoking | 1 | 2023 | 88 | 0.830 |
Why?
|
| Transfusion Reaction | 2 | 2013 | 102 | 0.810 |
Why?
|
| Thoracic Surgical Procedures | 3 | 2021 | 261 | 0.810 |
Why?
|
| Hearing Loss | 1 | 2023 | 153 | 0.810 |
Why?
|
| Brain Neoplasms | 6 | 2018 | 4849 | 0.810 |
Why?
|
| Laryngeal Neoplasms | 4 | 2021 | 518 | 0.800 |
Why?
|
| Male | 85 | 2023 | 123000 | 0.800 |
Why?
|
| Fentanyl | 4 | 2016 | 148 | 0.780 |
Why?
|
| Prostatectomy | 3 | 2019 | 962 | 0.780 |
Why?
|
| Female | 81 | 2024 | 141928 | 0.760 |
Why?
|
| Middle Aged | 64 | 2022 | 86204 | 0.750 |
Why?
|
| Sacroiliitis | 1 | 2020 | 4 | 0.750 |
Why?
|
| Postoperative Period | 7 | 2021 | 665 | 0.740 |
Why?
|
| Breast Neoplasms | 8 | 2024 | 15694 | 0.740 |
Why?
|
| Hyperalgesia | 6 | 2022 | 238 | 0.740 |
Why?
|
| Sepsis | 5 | 2023 | 652 | 0.730 |
Why?
|
| Esophageal Neoplasms | 4 | 2018 | 3168 | 0.720 |
Why?
|
| Blood Transfusion | 2 | 2021 | 583 | 0.710 |
Why?
|
| Benzodiazepines | 1 | 2021 | 170 | 0.700 |
Why?
|
| Anesthesiologists | 2 | 2023 | 49 | 0.700 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2023 | 228 | 0.690 |
Why?
|
| Arthralgia | 1 | 2020 | 89 | 0.690 |
Why?
|
| Inflammation | 3 | 2020 | 2522 | 0.690 |
Why?
|
| Aged | 53 | 2023 | 70117 | 0.680 |
Why?
|
| Killer Cells, Natural | 4 | 2017 | 904 | 0.680 |
Why?
|
| Thoracic Surgery, Video-Assisted | 2 | 2017 | 209 | 0.680 |
Why?
|
| Disease-Free Survival | 13 | 2020 | 10001 | 0.670 |
Why?
|
| Analgesics, Non-Narcotic | 4 | 2020 | 126 | 0.650 |
Why?
|
| Pulmonary Surgical Procedures | 2 | 2015 | 24 | 0.640 |
Why?
|
| Exosomes | 1 | 2021 | 253 | 0.640 |
Why?
|
| Thymectomy | 1 | 2018 | 79 | 0.640 |
Why?
|
| Atrial Fibrillation | 4 | 2023 | 719 | 0.640 |
Why?
|
| Tongue Neoplasms | 1 | 2020 | 246 | 0.640 |
Why?
|
| Anesthesia, Cardiac Procedures | 1 | 2018 | 29 | 0.640 |
Why?
|
| Preoperative Care | 5 | 2020 | 1529 | 0.630 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2023 | 598 | 0.630 |
Why?
|
| Troponin I | 1 | 2019 | 127 | 0.630 |
Why?
|
| Extracellular Traps | 3 | 2023 | 25 | 0.620 |
Why?
|
| Proportional Hazards Models | 10 | 2016 | 4988 | 0.620 |
Why?
|
| Cognitive Dysfunction | 1 | 2022 | 333 | 0.610 |
Why?
|
| Urology | 1 | 2019 | 128 | 0.600 |
Why?
|
| Myasthenia Gravis | 1 | 2018 | 99 | 0.600 |
Why?
|
| Fiber Optic Technology | 2 | 2017 | 142 | 0.600 |
Why?
|
| Biliary Tract Surgical Procedures | 1 | 2017 | 42 | 0.600 |
Why?
|
| Anesthesia, Inhalation | 1 | 2016 | 25 | 0.590 |
Why?
|
| Magnesium | 1 | 2017 | 160 | 0.580 |
Why?
|
| Carcinoma, Squamous Cell | 5 | 2021 | 5437 | 0.580 |
Why?
|
| Colorectal Neoplasms | 6 | 2020 | 3578 | 0.580 |
Why?
|
| Abdominal Neoplasms | 2 | 2018 | 231 | 0.580 |
Why?
|
| Gynecologic Surgical Procedures | 4 | 2021 | 356 | 0.570 |
Why?
|
| Isoflurane | 1 | 2016 | 67 | 0.570 |
Why?
|
| Laser Therapy | 2 | 2018 | 411 | 0.570 |
Why?
|
| Anesthetics, Inhalation | 1 | 2016 | 62 | 0.560 |
Why?
|
| Pain Threshold | 5 | 2008 | 130 | 0.550 |
Why?
|
| Recovery of Function | 2 | 2018 | 703 | 0.540 |
Why?
|
| Mediastinum | 1 | 2017 | 268 | 0.540 |
Why?
|
| Immunity, Cellular | 1 | 2017 | 419 | 0.530 |
Why?
|
| Lactic Acid | 1 | 2017 | 305 | 0.530 |
Why?
|
| Tumor Microenvironment | 3 | 2022 | 2864 | 0.520 |
Why?
|
| Propensity Score | 7 | 2023 | 750 | 0.520 |
Why?
|
| Evidence-Based Medicine | 1 | 2021 | 1085 | 0.520 |
Why?
|
| Ventricular Dysfunction | 1 | 2015 | 33 | 0.510 |
Why?
|
| Thymoma | 1 | 2018 | 246 | 0.510 |
Why?
|
| Equipment Design | 3 | 2017 | 1204 | 0.500 |
Why?
|
| Bronchoscopy | 2 | 2017 | 474 | 0.490 |
Why?
|
| Surgical Procedures, Operative | 2 | 2017 | 383 | 0.490 |
Why?
|
| Comorbidity | 2 | 2020 | 2352 | 0.480 |
Why?
|
| Cisplatin | 3 | 2019 | 2432 | 0.480 |
Why?
|
| Hepatectomy | 2 | 2017 | 1011 | 0.480 |
Why?
|
| Antineoplastic Agents | 8 | 2021 | 14289 | 0.470 |
Why?
|
| Lymphocytes | 2 | 2016 | 1234 | 0.460 |
Why?
|
| Thymus Neoplasms | 1 | 2018 | 400 | 0.450 |
Why?
|
| Neutrophils | 3 | 2023 | 835 | 0.450 |
Why?
|
| Laryngoscopy | 2 | 2012 | 183 | 0.450 |
Why?
|
| Hemodynamics | 1 | 2017 | 935 | 0.450 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2018 | 2594 | 0.440 |
Why?
|
| Bupivacaine | 4 | 2022 | 68 | 0.440 |
Why?
|
| Kaplan-Meier Estimate | 7 | 2020 | 6207 | 0.440 |
Why?
|
| Behavior, Animal | 4 | 2008 | 709 | 0.430 |
Why?
|
| Prognosis | 10 | 2021 | 21713 | 0.430 |
Why?
|
| Adult | 32 | 2023 | 77950 | 0.420 |
Why?
|
| Length of Stay | 9 | 2022 | 1900 | 0.420 |
Why?
|
| Mouth Neoplasms | 1 | 2017 | 713 | 0.420 |
Why?
|
| Video-Assisted Surgery | 1 | 2012 | 28 | 0.420 |
Why?
|
| Metalloproteases | 1 | 2011 | 24 | 0.410 |
Why?
|
| Acute Lung Injury | 2 | 2023 | 92 | 0.410 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2013 | 182 | 0.410 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2014 | 323 | 0.400 |
Why?
|
| Phosphopyruvate Hydratase | 1 | 2011 | 87 | 0.400 |
Why?
|
| Nerve Growth Factors | 1 | 2011 | 109 | 0.400 |
Why?
|
| S100 Proteins | 1 | 2011 | 181 | 0.390 |
Why?
|
| Intercostal Nerves | 3 | 2021 | 33 | 0.390 |
Why?
|
| Immune Tolerance | 1 | 2013 | 403 | 0.390 |
Why?
|
| Blood Preservation | 1 | 2011 | 54 | 0.380 |
Why?
|
| Head and Neck Neoplasms | 4 | 2021 | 3976 | 0.380 |
Why?
|
| Risk Factors | 11 | 2018 | 17523 | 0.380 |
Why?
|
| Dexamethasone | 1 | 2016 | 1450 | 0.380 |
Why?
|
| Survival Rate | 10 | 2021 | 12221 | 0.380 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2011 | 216 | 0.370 |
Why?
|
| Blood Coagulation | 1 | 2011 | 185 | 0.370 |
Why?
|
| Mastectomy | 1 | 2016 | 1534 | 0.360 |
Why?
|
| tau Proteins | 1 | 2011 | 216 | 0.350 |
Why?
|
| Drug Tolerance | 2 | 2020 | 114 | 0.350 |
Why?
|
| Cohort Studies | 8 | 2023 | 9244 | 0.350 |
Why?
|
| Combined Modality Therapy | 5 | 2021 | 8865 | 0.350 |
Why?
|
| Treatment Outcome | 18 | 2023 | 32848 | 0.350 |
Why?
|
| Spinal Cord | 3 | 2020 | 690 | 0.350 |
Why?
|
| Anesthesia, Intravenous | 3 | 2020 | 42 | 0.350 |
Why?
|
| Boronic Acids | 2 | 2011 | 362 | 0.340 |
Why?
|
| Hemorrhage | 3 | 2017 | 712 | 0.340 |
Why?
|
| Minocycline | 2 | 2022 | 182 | 0.340 |
Why?
|
| Thoracic Surgery | 2 | 2023 | 295 | 0.330 |
Why?
|
| Survival Analysis | 8 | 2020 | 9180 | 0.330 |
Why?
|
| Pyrazines | 2 | 2011 | 495 | 0.320 |
Why?
|
| Rats, Sprague-Dawley | 8 | 2022 | 2063 | 0.310 |
Why?
|
| Anticonvulsants | 1 | 2011 | 431 | 0.310 |
Why?
|
| Aspirin | 3 | 2017 | 455 | 0.310 |
Why?
|
| Multivariate Analysis | 4 | 2018 | 4298 | 0.300 |
Why?
|
| Ghrelin | 1 | 2007 | 79 | 0.300 |
Why?
|
| Electric Stimulation Therapy | 2 | 2009 | 116 | 0.300 |
Why?
|
| Disease Progression | 5 | 2020 | 6682 | 0.300 |
Why?
|
| Chronic Pain | 2 | 2022 | 238 | 0.300 |
Why?
|
| Nervous System Diseases | 1 | 2011 | 500 | 0.290 |
Why?
|
| Spine | 1 | 2008 | 293 | 0.290 |
Why?
|
| Liver Neoplasms | 3 | 2022 | 4557 | 0.290 |
Why?
|
| Hypnotics and Sedatives | 3 | 2023 | 218 | 0.290 |
Why?
|
| Interleukin-15 | 1 | 2008 | 185 | 0.290 |
Why?
|
| MicroRNAs | 1 | 2020 | 2947 | 0.290 |
Why?
|
| Clonidine | 3 | 2017 | 71 | 0.280 |
Why?
|
| Time Factors | 8 | 2018 | 12926 | 0.280 |
Why?
|
| Prostatic Neoplasms | 2 | 2015 | 5767 | 0.280 |
Why?
|
| Adrenergic alpha-2 Receptor Agonists | 3 | 2014 | 32 | 0.280 |
Why?
|
| Drug Therapy, Combination | 4 | 2017 | 2315 | 0.280 |
Why?
|
| Cachexia | 1 | 2007 | 161 | 0.280 |
Why?
|
| Double-Blind Method | 5 | 2023 | 2588 | 0.280 |
Why?
|
| Scalp | 2 | 2018 | 156 | 0.280 |
Why?
|
| Paclitaxel | 5 | 2015 | 1996 | 0.270 |
Why?
|
| Observational Studies as Topic | 3 | 2021 | 140 | 0.270 |
Why?
|
| Interleukin-2 | 2 | 2015 | 842 | 0.270 |
Why?
|
| Carcinoma | 1 | 2017 | 2578 | 0.260 |
Why?
|
| Thalidomide | 1 | 2008 | 569 | 0.250 |
Why?
|
| Antineoplastic Agents, Phytogenic | 5 | 2015 | 852 | 0.250 |
Why?
|
| Lung Diseases | 2 | 2021 | 717 | 0.250 |
Why?
|
| Hyperglycemia | 2 | 2017 | 333 | 0.240 |
Why?
|
| Rats | 8 | 2022 | 6086 | 0.230 |
Why?
|
| Postoperative Care | 3 | 2017 | 739 | 0.230 |
Why?
|
| Recurrence | 3 | 2020 | 4758 | 0.230 |
Why?
|
| Biomarkers | 5 | 2021 | 5047 | 0.230 |
Why?
|
| Young Adult | 12 | 2021 | 21445 | 0.230 |
Why?
|
| Epilepsy | 1 | 2011 | 883 | 0.230 |
Why?
|
| T-Lymphoma Invasion and Metastasis-inducing Protein 1 | 1 | 2022 | 24 | 0.220 |
Why?
|
| Masks | 1 | 2023 | 57 | 0.220 |
Why?
|
| Ganglia, Spinal | 2 | 2022 | 237 | 0.220 |
Why?
|
| Respiration, Artificial | 2 | 2018 | 577 | 0.220 |
Why?
|
| Animals | 17 | 2023 | 59536 | 0.220 |
Why?
|
| Morphine | 2 | 2023 | 308 | 0.220 |
Why?
|
| Hot Temperature | 3 | 2008 | 281 | 0.220 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2017 | 444 | 0.220 |
Why?
|
| Acetaminophen | 2 | 2020 | 116 | 0.220 |
Why?
|
| Robotic Surgical Procedures | 2 | 2019 | 481 | 0.220 |
Why?
|
| Prospective Studies | 4 | 2023 | 12873 | 0.210 |
Why?
|
| Child | 8 | 2022 | 29154 | 0.210 |
Why?
|
| Antiemetics | 1 | 2023 | 125 | 0.210 |
Why?
|
| Continuous Positive Airway Pressure | 1 | 2023 | 80 | 0.210 |
Why?
|
| Translations | 1 | 2022 | 39 | 0.210 |
Why?
|
| Administration, Intravenous | 3 | 2020 | 249 | 0.210 |
Why?
|
| Multicenter Studies as Topic | 2 | 2021 | 543 | 0.210 |
Why?
|
| Adenocarcinoma | 2 | 2018 | 7789 | 0.210 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 2023 | 108 | 0.210 |
Why?
|
| Immunosuppressive Agents | 1 | 2008 | 1375 | 0.210 |
Why?
|
| Interleukin-6 | 2 | 2017 | 1038 | 0.210 |
Why?
|
| Genital Neoplasms, Female | 2 | 2020 | 735 | 0.200 |
Why?
|
| Immunity, Innate | 3 | 2015 | 677 | 0.200 |
Why?
|
| Aged, 80 and over | 13 | 2021 | 29902 | 0.200 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2015 | 2796 | 0.200 |
Why?
|
| Nociception | 1 | 2021 | 45 | 0.200 |
Why?
|
| Video Recording | 2 | 2014 | 267 | 0.190 |
Why?
|
| Naltrexone | 1 | 2021 | 87 | 0.190 |
Why?
|
| Colorectal Surgery | 1 | 2020 | 32 | 0.190 |
Why?
|
| Fluid Therapy | 1 | 2022 | 182 | 0.190 |
Why?
|
| Abdominal Muscles | 1 | 2021 | 68 | 0.190 |
Why?
|
| Goals | 1 | 2022 | 185 | 0.190 |
Why?
|
| Clinical Trials as Topic | 2 | 2024 | 3719 | 0.190 |
Why?
|
| Critical Care | 2 | 2021 | 770 | 0.190 |
Why?
|
| Chemotherapy, Cancer, Regional Perfusion | 1 | 2021 | 169 | 0.190 |
Why?
|
| Narcotic Antagonists | 1 | 2021 | 129 | 0.190 |
Why?
|
| Neuromuscular Blockade | 1 | 2019 | 16 | 0.180 |
Why?
|
| Neostigmine | 1 | 2019 | 17 | 0.180 |
Why?
|
| Nausea | 1 | 2022 | 525 | 0.180 |
Why?
|
| Larynx | 1 | 2021 | 134 | 0.180 |
Why?
|
| Morbidity | 1 | 2021 | 397 | 0.180 |
Why?
|
| Shoulder Pain | 1 | 2019 | 31 | 0.180 |
Why?
|
| Hypnosis, Anesthetic | 1 | 2019 | 6 | 0.180 |
Why?
|
| Cell Communication | 2 | 2021 | 509 | 0.170 |
Why?
|
| Pancreatectomy | 2 | 2022 | 652 | 0.170 |
Why?
|
| Creatinine | 3 | 2016 | 531 | 0.170 |
Why?
|
| Colonoscopy | 1 | 2023 | 518 | 0.170 |
Why?
|
| Ultrasonography | 2 | 2017 | 1863 | 0.170 |
Why?
|
| Feasibility Studies | 2 | 2022 | 2292 | 0.170 |
Why?
|
| Oxygen | 1 | 2023 | 754 | 0.170 |
Why?
|
| Cetuximab | 1 | 2020 | 472 | 0.170 |
Why?
|
| Toll-Like Receptor 4 | 2 | 2022 | 203 | 0.170 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2019 | 110 | 0.170 |
Why?
|
| Pain, Procedural | 1 | 2018 | 14 | 0.170 |
Why?
|
| Laryngectomy | 2 | 2020 | 242 | 0.170 |
Why?
|
| Urologic Surgical Procedures | 1 | 2019 | 93 | 0.160 |
Why?
|
| Consciousness Monitors | 2 | 2019 | 3 | 0.160 |
Why?
|
| Medicare | 1 | 2023 | 860 | 0.160 |
Why?
|
| Mitomycin | 1 | 2019 | 208 | 0.160 |
Why?
|
| Neuropsychological Tests | 1 | 2022 | 1178 | 0.160 |
Why?
|
| Low Back Pain | 2 | 2009 | 83 | 0.160 |
Why?
|
| Adolescent | 10 | 2021 | 31252 | 0.160 |
Why?
|
| Mediastinoscopy | 1 | 2017 | 31 | 0.160 |
Why?
|
| Electrodes, Implanted | 2 | 2009 | 183 | 0.150 |
Why?
|
| Lipoxins | 1 | 2017 | 20 | 0.150 |
Why?
|
| Spinal Diseases | 1 | 2018 | 125 | 0.150 |
Why?
|
| Anesthetics, Intravenous | 2 | 2016 | 73 | 0.150 |
Why?
|
| Obesity | 2 | 2023 | 2884 | 0.150 |
Why?
|
| Lumbar Vertebrae | 2 | 2009 | 245 | 0.150 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2021 | 15862 | 0.150 |
Why?
|
| Leukocyte Count | 2 | 2016 | 684 | 0.150 |
Why?
|
| Docosahexaenoic Acids | 1 | 2017 | 79 | 0.150 |
Why?
|
| Neuronavigation | 1 | 2017 | 47 | 0.150 |
Why?
|
| Communication | 1 | 2023 | 876 | 0.140 |
Why?
|
| Abdomen | 1 | 2018 | 332 | 0.140 |
Why?
|
| Laparoscopy | 2 | 2019 | 1225 | 0.140 |
Why?
|
| SEER Program | 1 | 2019 | 1000 | 0.140 |
Why?
|
| Vincristine | 2 | 2012 | 1511 | 0.140 |
Why?
|
| Hydrocortisone | 1 | 2017 | 388 | 0.140 |
Why?
|
| Neoplasm Metastasis | 2 | 2018 | 5112 | 0.140 |
Why?
|
| Posterior Horn Cells | 2 | 2008 | 125 | 0.140 |
Why?
|
| Delivery of Health Care | 1 | 2023 | 860 | 0.140 |
Why?
|
| Tooth Socket | 1 | 2015 | 3 | 0.130 |
Why?
|
| Sensation Disorders | 2 | 2006 | 27 | 0.130 |
Why?
|
| Blood Platelets | 2 | 2021 | 731 | 0.130 |
Why?
|
| Anti-Bacterial Agents | 1 | 2008 | 2992 | 0.130 |
Why?
|
| Spinal Cord Compression | 1 | 2017 | 151 | 0.130 |
Why?
|
| Intubation | 1 | 2015 | 40 | 0.130 |
Why?
|
| Trismus | 1 | 2015 | 24 | 0.130 |
Why?
|
| TRPV Cation Channels | 1 | 2015 | 76 | 0.130 |
Why?
|
| Health Care Costs | 1 | 2020 | 674 | 0.130 |
Why?
|
| Esophagogastric Junction | 1 | 2018 | 543 | 0.130 |
Why?
|
| Electroencephalography | 1 | 2019 | 898 | 0.120 |
Why?
|
| Software | 1 | 2022 | 1321 | 0.120 |
Why?
|
| Cytokines | 2 | 2014 | 2809 | 0.120 |
Why?
|
| Platelet Count | 2 | 2016 | 490 | 0.120 |
Why?
|
| Diastole | 1 | 2015 | 187 | 0.120 |
Why?
|
| Ultrasonography, Interventional | 1 | 2017 | 429 | 0.120 |
Why?
|
| Thrombosis | 1 | 2021 | 781 | 0.120 |
Why?
|
| Fatty Acids, Nonesterified | 1 | 2014 | 159 | 0.120 |
Why?
|
| Sensory Receptor Cells | 1 | 2015 | 141 | 0.120 |
Why?
|
| Cell Proliferation | 3 | 2021 | 7226 | 0.120 |
Why?
|
| United States | 4 | 2023 | 15433 | 0.120 |
Why?
|
| Neoplasm Staging | 4 | 2019 | 13658 | 0.120 |
Why?
|
| Tracheostomy | 1 | 2016 | 243 | 0.120 |
Why?
|
| Intraoperative Period | 1 | 2014 | 246 | 0.120 |
Why?
|
| Mandible | 1 | 2015 | 188 | 0.120 |
Why?
|
| Deep Brain Stimulation | 2 | 2009 | 348 | 0.120 |
Why?
|
| Pancreatic Neoplasms | 2 | 2022 | 5061 | 0.120 |
Why?
|
| Epinephrine | 1 | 2014 | 255 | 0.120 |
Why?
|
| Smoking | 1 | 2023 | 2440 | 0.120 |
Why?
|
| Hydromorphone | 1 | 2013 | 58 | 0.120 |
Why?
|
| Colchicine | 2 | 2023 | 52 | 0.120 |
Why?
|
| Mastectomy, Segmental | 1 | 2019 | 1026 | 0.120 |
Why?
|
| Methyl Ethers | 1 | 2013 | 28 | 0.110 |
Why?
|
| Pancreaticoduodenectomy | 1 | 2017 | 690 | 0.110 |
Why?
|
| Amides | 1 | 2013 | 123 | 0.110 |
Why?
|
| Body Weight | 2 | 2008 | 1293 | 0.110 |
Why?
|
| Anesthesia, Local | 1 | 2013 | 66 | 0.110 |
Why?
|
| Infusions, Intravenous | 3 | 2022 | 1382 | 0.110 |
Why?
|
| Epigenesis, Genetic | 1 | 2020 | 1399 | 0.110 |
Why?
|
| Intraoperative Complications | 2 | 2013 | 301 | 0.110 |
Why?
|
| Surgical Wound Infection | 1 | 2016 | 450 | 0.110 |
Why?
|
| Supratentorial Neoplasms | 1 | 2013 | 78 | 0.110 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2017 | 342 | 0.110 |
Why?
|
| Physical Stimulation | 2 | 2012 | 112 | 0.110 |
Why?
|
| Reoperation | 1 | 2017 | 1382 | 0.110 |
Why?
|
| Lymphocyte Activation | 1 | 2017 | 1688 | 0.110 |
Why?
|
| Follow-Up Studies | 7 | 2017 | 14889 | 0.100 |
Why?
|
| S100 Calcium Binding Protein beta Subunit | 1 | 2011 | 13 | 0.100 |
Why?
|
| Delphi Technique | 2 | 2023 | 210 | 0.100 |
Why?
|
| Thermosensing | 2 | 2012 | 9 | 0.100 |
Why?
|
| Pneumonectomy | 1 | 2017 | 831 | 0.100 |
Why?
|
| Thoracotomy | 1 | 2013 | 220 | 0.100 |
Why?
|
| Natural Killer T-Cells | 1 | 2013 | 124 | 0.100 |
Why?
|
| Spinal Neoplasms | 1 | 2017 | 631 | 0.100 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2012 | 113 | 0.100 |
Why?
|
| Induction Chemotherapy | 1 | 2015 | 669 | 0.100 |
Why?
|
| Recovery Room | 1 | 2011 | 7 | 0.100 |
Why?
|
| Blood Coagulation Tests | 1 | 2011 | 87 | 0.100 |
Why?
|
| Touch | 2 | 2012 | 71 | 0.100 |
Why?
|
| Anesthesia Recovery Period | 1 | 2011 | 36 | 0.100 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2020 | 1249 | 0.100 |
Why?
|
| Blood Transfusion, Autologous | 1 | 2011 | 68 | 0.100 |
Why?
|
| Intracranial Arteriovenous Malformations | 1 | 2011 | 41 | 0.100 |
Why?
|
| Consciousness Disorders | 1 | 2011 | 34 | 0.100 |
Why?
|
| Endarterectomy, Carotid | 1 | 2011 | 121 | 0.100 |
Why?
|
| Infratentorial Neoplasms | 1 | 2011 | 45 | 0.100 |
Why?
|
| Stress, Physiological | 1 | 2014 | 492 | 0.090 |
Why?
|
| Manikins | 1 | 2011 | 137 | 0.090 |
Why?
|
| Neurologic Examination | 1 | 2011 | 245 | 0.090 |
Why?
|
| Health Status | 1 | 2013 | 590 | 0.090 |
Why?
|
| Laryngoscopes | 1 | 2011 | 86 | 0.090 |
Why?
|
| Sensory Thresholds | 2 | 2012 | 68 | 0.090 |
Why?
|
| Operating Rooms | 1 | 2011 | 122 | 0.090 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2022 | 2027 | 0.090 |
Why?
|
| Antihypertensive Agents | 2 | 2017 | 395 | 0.090 |
Why?
|
| Intervertebral Disc Displacement | 1 | 2009 | 28 | 0.090 |
Why?
|
| Cell Line, Tumor | 3 | 2021 | 14551 | 0.090 |
Why?
|
| Mice, Nude | 3 | 2021 | 4307 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2015 | 4938 | 0.090 |
Why?
|
| Adrenalectomy | 1 | 2010 | 188 | 0.090 |
Why?
|
| Bortezomib | 2 | 2011 | 543 | 0.080 |
Why?
|
| Immunocompromised Host | 1 | 2013 | 698 | 0.080 |
Why?
|
| Age Factors | 3 | 2013 | 5377 | 0.080 |
Why?
|
| Cardiopulmonary Bypass | 1 | 2011 | 422 | 0.080 |
Why?
|
| Transforming Growth Factor beta | 1 | 2014 | 1130 | 0.080 |
Why?
|
| Sacroiliac Joint | 1 | 2008 | 19 | 0.080 |
Why?
|
| Rotarod Performance Test | 1 | 2008 | 26 | 0.080 |
Why?
|
| Blood Loss, Surgical | 1 | 2011 | 309 | 0.080 |
Why?
|
| Sex Factors | 1 | 2013 | 2139 | 0.080 |
Why?
|
| Locomotion | 1 | 2008 | 84 | 0.080 |
Why?
|
| Mice | 7 | 2023 | 34495 | 0.080 |
Why?
|
| Psychomotor Performance | 2 | 2006 | 233 | 0.080 |
Why?
|
| Electrophysiology | 1 | 2008 | 333 | 0.080 |
Why?
|
| Injections, Spinal | 1 | 2008 | 257 | 0.080 |
Why?
|
| Chemoradiotherapy | 1 | 2016 | 1946 | 0.080 |
Why?
|
| Reaction Time | 1 | 2008 | 234 | 0.080 |
Why?
|
| Arthritis | 1 | 2008 | 139 | 0.080 |
Why?
|
| Nociceptors | 2 | 2005 | 86 | 0.080 |
Why?
|
| Pheochromocytoma | 1 | 2010 | 281 | 0.080 |
Why?
|
| Chronic Disease | 3 | 2008 | 1819 | 0.080 |
Why?
|
| Salvage Therapy | 1 | 2016 | 2054 | 0.080 |
Why?
|
| Electric Stimulation | 1 | 2008 | 426 | 0.070 |
Why?
|
| Prostate-Specific Antigen | 1 | 2011 | 993 | 0.070 |
Why?
|
| Cryosurgery | 1 | 2008 | 167 | 0.070 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2020 | 5178 | 0.070 |
Why?
|
| Cold Temperature | 1 | 2006 | 121 | 0.070 |
Why?
|
| Sensation | 1 | 2006 | 71 | 0.070 |
Why?
|
| Drug Administration Schedule | 3 | 2018 | 3472 | 0.070 |
Why?
|
| Cell Differentiation | 1 | 2017 | 4078 | 0.070 |
Why?
|
| Fenoldopam | 1 | 2006 | 12 | 0.070 |
Why?
|
| Biomedical Research | 1 | 2013 | 806 | 0.070 |
Why?
|
| Quality of Life | 1 | 2020 | 4532 | 0.070 |
Why?
|
| Predictive Value of Tests | 1 | 2015 | 4892 | 0.070 |
Why?
|
| Statistics, Nonparametric | 1 | 2008 | 980 | 0.070 |
Why?
|
| Drug Interactions | 1 | 2007 | 553 | 0.070 |
Why?
|
| Amino Acid Transport System X-AG | 1 | 2005 | 12 | 0.070 |
Why?
|
| Excitatory Amino Acid Transporter 2 | 1 | 2005 | 27 | 0.070 |
Why?
|
| Body Mass Index | 1 | 2013 | 2203 | 0.070 |
Why?
|
| Stomach Neoplasms | 1 | 2018 | 2278 | 0.070 |
Why?
|
| Brain | 1 | 2019 | 4113 | 0.070 |
Why?
|
| Risk Assessment | 1 | 2018 | 6869 | 0.070 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2010 | 489 | 0.070 |
Why?
|
| Prosthesis Implantation | 1 | 2008 | 263 | 0.070 |
Why?
|
| Eating | 1 | 2007 | 421 | 0.060 |
Why?
|
| Kidney | 2 | 2022 | 2146 | 0.060 |
Why?
|
| Venous Thrombosis | 1 | 2008 | 384 | 0.060 |
Why?
|
| Symporters | 1 | 2005 | 98 | 0.060 |
Why?
|
| Practice Guidelines as Topic | 1 | 2015 | 2403 | 0.060 |
Why?
|
| Reperfusion Injury | 1 | 2006 | 145 | 0.060 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2007 | 630 | 0.060 |
Why?
|
| Mice, Inbred C57BL | 3 | 2021 | 6942 | 0.060 |
Why?
|
| Droperidol | 1 | 2023 | 3 | 0.060 |
Why?
|
| Liposomes | 2 | 2017 | 684 | 0.060 |
Why?
|
| Administration, Oral | 2 | 2020 | 1544 | 0.060 |
Why?
|
| Nerve Fibers, Myelinated | 1 | 2004 | 122 | 0.060 |
Why?
|
| Ontario | 1 | 2023 | 98 | 0.060 |
Why?
|
| Postoperative Nausea and Vomiting | 1 | 2023 | 51 | 0.060 |
Why?
|
| Cell Movement | 2 | 2021 | 2466 | 0.060 |
Why?
|
| Catheter Ablation | 1 | 2008 | 620 | 0.060 |
Why?
|
| Neoplasm Invasiveness | 2 | 2021 | 3981 | 0.050 |
Why?
|
| Bone Neoplasms | 1 | 2015 | 2576 | 0.050 |
Why?
|
| Sufentanil | 1 | 2022 | 8 | 0.050 |
Why?
|
| Lung | 1 | 2013 | 3151 | 0.050 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2021 | 3821 | 0.050 |
Why?
|
| Alveolar Epithelial Cells | 1 | 2022 | 46 | 0.050 |
Why?
|
| Microcirculation | 1 | 2023 | 200 | 0.050 |
Why?
|
| Policy | 1 | 2022 | 49 | 0.050 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2011 | 1237 | 0.050 |
Why?
|
| Interferon-beta | 1 | 2022 | 102 | 0.050 |
Why?
|
| Matched-Pair Analysis | 1 | 2021 | 103 | 0.050 |
Why?
|
| Incidence | 2 | 2023 | 5673 | 0.050 |
Why?
|
| Biomarkers, Tumor | 1 | 2021 | 10331 | 0.050 |
Why?
|
| Educational Status | 1 | 2023 | 397 | 0.050 |
Why?
|
| Infant | 1 | 2017 | 13310 | 0.050 |
Why?
|
| Quaternary Ammonium Compounds | 1 | 2021 | 67 | 0.050 |
Why?
|
| Adenosine | 1 | 2023 | 289 | 0.050 |
Why?
|
| Myeloid Differentiation Factor 88 | 1 | 2022 | 155 | 0.050 |
Why?
|
| Methyltransferases | 1 | 2022 | 148 | 0.050 |
Why?
|
| Glottis | 1 | 2021 | 67 | 0.050 |
Why?
|
| Disease Management | 1 | 2006 | 1052 | 0.050 |
Why?
|
| Child, Preschool | 1 | 2017 | 16273 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2017 | 7702 | 0.050 |
Why?
|
| Neuronal Plasticity | 1 | 2022 | 304 | 0.050 |
Why?
|
| HCT116 Cells | 1 | 2020 | 348 | 0.050 |
Why?
|
| Antidepressive Agents | 1 | 2022 | 332 | 0.040 |
Why?
|
| Lymphoma, B-Cell | 1 | 2006 | 895 | 0.040 |
Why?
|
| Endpoint Determination | 1 | 2020 | 176 | 0.040 |
Why?
|
| Lipopolysaccharides | 1 | 2022 | 558 | 0.040 |
Why?
|
| Diarrhea | 1 | 2023 | 686 | 0.040 |
Why?
|
| Arterial Pressure | 1 | 2019 | 107 | 0.040 |
Why?
|
| Anti-Anxiety Agents | 1 | 2019 | 90 | 0.040 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2020 | 460 | 0.040 |
Why?
|
| Time | 1 | 2018 | 178 | 0.040 |
Why?
|
| Consensus | 1 | 2022 | 978 | 0.040 |
Why?
|
| Disability Evaluation | 2 | 2009 | 249 | 0.040 |
Why?
|
| Up-Regulation | 1 | 2023 | 2450 | 0.040 |
Why?
|
| Signal Transduction | 3 | 2021 | 11965 | 0.040 |
Why?
|
| Endothelial Cells | 1 | 2023 | 1048 | 0.040 |
Why?
|
| ras Proteins | 1 | 2020 | 770 | 0.040 |
Why?
|
| Fluoroscopy | 1 | 2017 | 232 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2020 | 2314 | 0.030 |
Why?
|
| Molar | 1 | 2015 | 12 | 0.030 |
Why?
|
| Outpatients | 1 | 2019 | 462 | 0.030 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2021 | 973 | 0.030 |
Why?
|
| Pilot Projects | 2 | 2012 | 2803 | 0.030 |
Why?
|
| Multiple Myeloma | 1 | 2006 | 2138 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2021 | 1987 | 0.030 |
Why?
|
| Patient Positioning | 1 | 2017 | 195 | 0.030 |
Why?
|
| Hydroxyeicosatetraenoic Acids | 1 | 2014 | 35 | 0.030 |
Why?
|
| Interleukin-4 | 1 | 2015 | 284 | 0.030 |
Why?
|
| Linoleic Acid | 1 | 2014 | 29 | 0.030 |
Why?
|
| Administration, Cutaneous | 1 | 2014 | 141 | 0.030 |
Why?
|
| Patch-Clamp Techniques | 1 | 2015 | 388 | 0.030 |
Why?
|
| Standard of Care | 1 | 2016 | 243 | 0.030 |
Why?
|
| Injections | 1 | 2015 | 285 | 0.030 |
Why?
|
| Excitatory Postsynaptic Potentials | 1 | 2015 | 245 | 0.030 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2014 | 94 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2017 | 1323 | 0.030 |
Why?
|
| K562 Cells | 1 | 2015 | 338 | 0.030 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2020 | 1546 | 0.030 |
Why?
|
| Phospholipids | 1 | 2014 | 177 | 0.030 |
Why?
|
| Skin | 2 | 2012 | 1259 | 0.030 |
Why?
|
| Mechanoreceptors | 1 | 2012 | 28 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2020 | 2054 | 0.030 |
Why?
|
| Hypotension | 1 | 2014 | 210 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2014 | 700 | 0.030 |
Why?
|
| Depression | 1 | 2022 | 1715 | 0.030 |
Why?
|
| Nerve Fibers | 1 | 2012 | 106 | 0.030 |
Why?
|
| Analysis of Variance | 2 | 2008 | 2307 | 0.030 |
Why?
|
| Carcinogenesis | 1 | 2019 | 1026 | 0.030 |
Why?
|
| Motor Skills | 1 | 2012 | 107 | 0.030 |
Why?
|
| ErbB Receptors | 1 | 2020 | 2295 | 0.030 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2019 | 1415 | 0.030 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2017 | 799 | 0.030 |
Why?
|
| Ohio | 1 | 2011 | 113 | 0.030 |
Why?
|
| Patient Safety | 1 | 2017 | 649 | 0.020 |
Why?
|
| Apoptosis | 1 | 2006 | 7591 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2015 | 1489 | 0.020 |
Why?
|
| Task Performance and Analysis | 1 | 2011 | 136 | 0.020 |
Why?
|
| Catheterization | 1 | 2013 | 410 | 0.020 |
Why?
|
| Glomerular Filtration Rate | 1 | 2014 | 602 | 0.020 |
Why?
|
| Prevalence | 1 | 2018 | 3260 | 0.020 |
Why?
|
| Risk | 1 | 2014 | 1972 | 0.020 |
Why?
|
| Cross-Over Studies | 1 | 2011 | 460 | 0.020 |
Why?
|
| Diskectomy | 1 | 2009 | 10 | 0.020 |
Why?
|
| Calcium | 1 | 2015 | 1537 | 0.020 |
Why?
|
| Electrodes | 1 | 2008 | 116 | 0.020 |
Why?
|
| Myocardial Infarction | 1 | 2017 | 1374 | 0.020 |
Why?
|
| Dystonic Disorders | 1 | 2009 | 81 | 0.020 |
Why?
|
| Afferent Pathways | 1 | 2007 | 64 | 0.020 |
Why?
|
| Research Design | 1 | 2014 | 1544 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2011 | 2316 | 0.020 |
Why?
|
| Glutamate Plasma Membrane Transport Proteins | 1 | 2005 | 5 | 0.020 |
Why?
|
| Excitatory Amino Acid Transporter 1 | 1 | 2005 | 8 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2014 | 4971 | 0.020 |
Why?
|
| DNA Fragmentation | 1 | 2006 | 198 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2021 | 8873 | 0.020 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2014 | 787 | 0.020 |
Why?
|
| Presynaptic Terminals | 1 | 2005 | 114 | 0.020 |
Why?
|
| Biopsy | 1 | 2012 | 3443 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2014 | 6100 | 0.020 |
Why?
|
| Random Allocation | 1 | 2006 | 703 | 0.020 |
Why?
|
| Logistic Models | 1 | 2011 | 3441 | 0.020 |
Why?
|
| Neuroglia | 1 | 2005 | 223 | 0.010 |
Why?
|
| Glutamic Acid | 1 | 2005 | 309 | 0.010 |
Why?
|
| Clinical Competence | 1 | 2011 | 1270 | 0.010 |
Why?
|
| Models, Animal | 1 | 2006 | 664 | 0.010 |
Why?
|
| Patient Satisfaction | 1 | 2008 | 915 | 0.010 |
Why?
|
| Synaptic Transmission | 1 | 2005 | 443 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2005 | 2074 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2006 | 2508 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2006 | 3154 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2005 | 7222 | 0.010 |
Why?
|